Welcome to LookChem.com Sign In|Join Free

CAS

  • or

869299-42-3

Post Buying Request

869299-42-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

869299-42-3 Usage

Description

Ethyl quinazoline-2-carboxylate is a chemical compound with the molecular formula C12H10N2O2, belonging to the quinazoline class of compounds known for their diverse pharmacological activities. It has been studied for its potential therapeutic properties, including its ability to act as an inhibitor of certain enzymes and as a potential anti-inflammatory and anti-cancer agent. Ethyl quinazoline-2-carboxylate is synthesized by the esterification of quinazoline-2-carboxylic acid with ethanol and is typically used in research settings for its pharmaceutical and medicinal properties.

Uses

Used in Pharmaceutical Research:
Ethyl quinazoline-2-carboxylate is used as a research compound for its potential therapeutic applications, particularly in the development of new drugs targeting various diseases.
Used in Drug Discovery and Development:
Ethyl quinazoline-2-carboxylate is used as a lead compound in drug discovery and development, due to its potential as an enzyme inhibitor and its anti-inflammatory and anti-cancer properties.
Used in Enzyme Inhibition:
Ethyl quinazoline-2-carboxylate is used as an enzyme inhibitor, which can be beneficial in treating certain conditions by regulating enzyme activity.
Used in Anti-inflammatory Applications:
Ethyl quinazoline-2-carboxylate is used as an anti-inflammatory agent, potentially helping to reduce inflammation and alleviate symptoms associated with inflammatory conditions.
Used in Anti-cancer Applications:
Ethyl quinazoline-2-carboxylate is used as a potential anti-cancer agent, with the capacity to target and inhibit the growth of cancer cells, making it a promising candidate for cancer treatment research.

Check Digit Verification of cas no

The CAS Registry Mumber 869299-42-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,9,2,9 and 9 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 869299-42:
(8*8)+(7*6)+(6*9)+(5*2)+(4*9)+(3*9)+(2*4)+(1*2)=243
243 % 10 = 3
So 869299-42-3 is a valid CAS Registry Number.
InChI:InChI=1/C11H10N2O2/c1-2-15-11(14)10-12-7-8-5-3-4-6-9(8)13-10/h3-7H,2H2,1H3

869299-42-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name Ethyl quinazoline-2-carboxylate

1.2 Other means of identification

Product number -
Other names ethylquinazoline-2-carboxylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:869299-42-3 SDS

869299-42-3Downstream Products

869299-42-3Relevant articles and documents

Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3′-carboxamido)morphinan analogues as opioid receptor ligands

Yuan, Yunyun,Zaidi, Saheem A.,Stevens, David L.,Scoggins, Krista L.,Mosier, Philip D.,Kellogg, Glen E.,Dewey, William L.,Selley, Dana E.,Zhang, Yan

supporting information, p. 1701 - 1715 (2015/03/30)

A series of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3′-carboxamido)morphinan (NAQ) analogues were synthesized and pharmacologically characterized to study their structure-activity relationship at the mu opioid receptor (MOR). The competition binding assay showed two-atom spacer and aromatic side chain were optimal for MOR selectivity. Meanwhile, substitutions at the 1′- and/or 4′-position of the isoquinoline ring retained or improved MOR selectivity over the kappa opioid receptor while still possessing above 20-fold MOR selectivity over the delta opioid receptor. In contrast, substitutions at the 6′- and/or 7′-position of the isoquinoline ring reduced MOR selectivity as well as MOR efficacy. Among this series of ligands, compound 11 acted as an antagonist when challenged with morphine in warm-water tail immersion assay and produced less significant withdrawal symptoms compared to naltrexone in morphine-pelleted mice. Compound 11 also antagonized the intracellular Ca2+ increase induced by DAMGO. Molecular dynamics simulation studies of 11 in three opioid receptors indicated orientation of the 6′-nitro group varied significantly in the different 'address' domains of the receptors and played a crucial role in the observed binding affinities and selectivity. Collectively, the current findings provide valuable insights for future development of NAQ-based MOR selective ligands.

Structure activity relationship studies of 17-cyclopropylmethyl-3,14β- dihydroxy-4,5α-epoxy-6α-(isoquinoline-3′-carboxamido) morphinan (NAQ) analogues as potent opioid receptor ligands: Preliminary results on the role of electronic characteristics for affinity and function

Yuan, Yunyun,Elbegdorj, Orgil,Beletskaya, Irina O.,Selley, Dana E.,Zhang, Yan

supporting information, p. 5045 - 5048 (2013/09/12)

17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α- (isoquinoline-3′-carboxamido)morphinan (NAQ) was previously designed following the 'message-address' concept and was identified as a potent and highly selective mu opioid receptor (MOR) ligand based on its pharmacological profile. We here report the preliminary structure activity relationship (SAR) studies of this novel lead compound. For the new ligands synthesized as NAQ analogues, their binding assay results showed that a longer spacer and a saturated ring system of the side chain were unfavorable for their MOR selectivity over the kappa and delta opioid receptors. In contrast, substitutions with different electronic properties at either 1′- or 4′-position of the isoquinoline ring of the side chain were generally acceptable for reasonable MOR selectivity. The majority of NAQ analogues retained low efficacy at the MOR compared to NAQ in the 35S- GTP[γS] binding assays while electron-withdrawing groups at 1′-position of the isoquinoline ring induced higher MOR stimulation than electron-donating groups did. In summary, the electronic characteristics of substituents at 1′- or 4′-position of the isoquinoline ring in NAQ seem to be critical and need to be further tuned up to achieve higher MOR selectivity and lower MOR stimulation.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 869299-42-3